Page 139 - 2019_05-HaematologicaMondo-web

CD147 as potential therapeutic target in AML
36. Spring FA, Holmes CH, Simpson KL, et al. The Oka blood group antigen is a marker for the M6 leukocyte activation antigen, the human homolog of OX-47 antigen, basigin and neurothelin, an immunoglobu- lin superfamily molecule that is widely expressed in human cells and tissues. Eur J Immunol. 1997;27(4):891-897.
37. Coste I, Gauchat JF, Wilson A, et al. Unavailability of CD147 leads to selective erythrocyte trapping in the spleen. Blood. 2001;97(12):3984-3988.
38. Xiong A, Yang Z, Shen Y, Zhou J, Shen Q. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel). 2014;6(2):926-957.
39. Murone M, Radpour R, Attinger A, et al. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+
Stem/Progenitor Cells. Mol Cancer Ther.
2017;16(8):1497-1510.
40. Xiang M, Kim H, Ho VT, et al. Gene
expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016;128(14):1845-1853.
41. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809.
42. Evangelisti C, Evangelisti C, Chiarini F, et al. Autophagy in acute leukemias: a dou- ble-edged sword with important therapeu- tic implications. Biochim Biophys Acta. 2015;1853(1):14-26.
43. Wei Y, Kadia T, Tong W, et al. The combi- nation of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimet- ic GX15-070 has synergistic antileukemia activity by activating both apoptosis and
autophagy. Clin Cancer Res. 2010;
16(15):3923-3932.
44. Auberger P, Puissant A. Autophagy, a key
mechanism of oncogenesis and resistance
in leukemia. Blood. 2017;129(5):547-552. 45. Zhao S, Guo J, Zhao Y, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by sup- pressing JAK2/STAT3 signaling. Am J
Transl Res. 2016;8(7):3169-3178.
46. Li X, Yan X, Guo W, et al. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine. Biomed Pharmacother.
2017;90:699-704.
47. Wang YY, Chen WL, Weng XQ, et al. Low
CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34+ Acute Myeloid Leukemia. Stem Cells Dev. 2017;26(20):1460-1467.
haematologica | 2019; 104(5)
985